Targeting ATM and ATR for cancer therapeutics: inhibitors in clinic.

[1]  R. Plummer,et al.  Abstract CT272: Pharmacodynamic and immunophenotyping analyses of ATR inhibitor M1774 in a Phase I study in patients with solid tumors (DDRiver Solid Tumors 301) , 2023, Cancer Research.

[2]  R. Plummer,et al.  Abstract CT271: Translational analyses of ATR inhibitor M1774 in a Phase I study in patients with solid tumors (DDRiver Solid Tumors 301) , 2023, Cancer Research.

[3]  E. Brown,et al.  Abstract 6177: ATRN-119 and ATRN-W1051: Novel and potentially well tolerated ATR and WEE1 inhibitors for targeted cancer treatment , 2023, Cancer Research.

[4]  V. Grinkevich,et al.  Abstract 312: The ATR inhibitor ART0380 shows preclinical efficacy in monotherapy or in combination with gemcitabine, aPD1, PARP inhibitors and topoisomerase 1 poisons , 2023, Cancer Research.

[5]  L. Vassilev,et al.  Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell death , 2023, Aging.

[6]  E. Ratner,et al.  Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. , 2022, Gynecologic oncology.

[7]  T. Pitts,et al.  ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer , 2022, BMC Cancer.

[8]  B. Ploeger,et al.  Optimization of treatment schedule for the ATR inhibitor elimusertib (BAY 1895344) in preclinical tumor models , 2022, European Journal of Cancer.

[9]  R. Plummer,et al.  457MO A phase I study of ATR inhibitor M1774 in patients with solid tumours (DDRiver Solid Tumours 301): Part A1 results , 2022, Annals of Oncology.

[10]  S. Milano,et al.  Evolving Experimental Techniques for Structure-Based Drug Design. , 2022, The journal of physical chemistry. B.

[11]  W. Park,et al.  Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer , 2022, Journal for ImmunoTherapy of Cancer.

[12]  L. Vassilev,et al.  A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies , 2022, Molecular cancer therapeutics.

[13]  R. Plummer,et al.  5MO Comprehensive dose-finding strategy for single-agent RP-3500, a highly selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase , 2022, Annals of Oncology.

[14]  A. Lau,et al.  ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib , 2022, Cancer research.

[15]  R. Stocco,et al.  RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors , 2021, Molecular Cancer Therapeutics.

[16]  N. Pavletich,et al.  Structure of the human ATM kinase and mechanism of Nbs1 binding , 2021, bioRxiv.

[17]  W. Park,et al.  Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD1 therapy. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  A. Alt,et al.  Molecular basis of human ATM kinase inhibition , 2021, Nature Structural & Molecular Biology.

[19]  Y. Matsumoto,et al.  DNA-Dependent Protein Kinase Catalytic Subunit: The Sensor for DNA Double-Strand Breaks Structurally and Functionally Related to Ataxia Telangiectasia Mutated , 2021, Genes.

[20]  R. Plummer,et al.  Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours , 2021, British Journal of Cancer.

[21]  J. Ahn,et al.  The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer. , 2021 .

[22]  S. Steinberg,et al.  Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. , 2021, Cancer cell.

[23]  C. Halldin,et al.  Brain exposure of the ATM inhibitor AZD1390 in humans - a positron emission tomography (PET) study. , 2020, Neuro-oncology.

[24]  Sugata Barui,et al.  Synthesis and Characterization of Quinoline-3-Carboxamide Derivatives as Inhibitors of the ATM Kinase. , 2020, Current topics in medicinal chemistry.

[25]  E. Kohn,et al.  Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. , 2020, The Lancet. Oncology.

[26]  A. Lau,et al.  Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells , 2020, Oncogene.

[27]  T. J. McCorvie,et al.  Structural basis of homologous recombination , 2019, Cellular and Molecular Life Sciences.

[28]  D. Oh,et al.  ATM in DNA repair in cancer. , 2019, Pharmacology & therapeutics.

[29]  Daniel Kuhn,et al.  Abstract 3500: Highly potent and selective ATM kinase inhibitor M4076: A clinical candidate drug with strong anti-tumor activity in combination therapies , 2019, Molecular and Cellular Biology / Genetics.

[30]  B. Elenbaas,et al.  Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy , 2019, Experimental and Molecular Therapeutics.

[31]  L. Rubinstein,et al.  Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors. , 2019, Journal of Clinical Oncology.

[32]  Liewei Wang,et al.  UFL1 promotes histone H4 ufmylation and ATM activation , 2019, Nature Communications.

[33]  Wei-Guo Zhu,et al.  MRE11 UFMylation promotes ATM activation , 2019, Nucleic acids research.

[34]  I. Barrett,et al.  The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models , 2018, Science Advances.

[35]  L. Rubinstein,et al.  Phase I trial of the triplet M6620 (formerly VX970) + veliparib + cisplatin in patients with advanced solid tumors. , 2018 .

[36]  Fengtang Yang,et al.  ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks , 2018, bioRxiv.

[37]  Nichola L. Davies,et al.  The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one). , 2018, Journal of medicinal chemistry.

[38]  Michael T. Zimmermann,et al.  Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas , 2018, Cell reports.

[39]  Chen Ding,et al.  Cryo-EM structure of human ATR-ATRIP complex , 2017, Cell Research.

[40]  L. Tora,et al.  Sharing the SAGA. , 2017, Trends in biochemical sciences.

[41]  Sipei Wu,et al.  XRRA1 Targets ATM/CHK1/2-Mediated DNA Repair in Colorectal Cancer , 2017, BioMed research international.

[42]  L. Zou,et al.  A phosphorylation-and-ubiquitylation circuitry driving ATR activation and homologous recombination , 2017, Nucleic acids research.

[43]  S. Jackson,et al.  ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. , 2017, Molecular cell.

[44]  G. Walker,et al.  Mechanisms of DNA damage, repair, and mutagenesis , 2017, Environmental and molecular mutagenesis.

[45]  W. Haas,et al.  Coupling of Homologous Recombination and the Checkpoint by ATR. , 2017, Molecular cell.

[46]  Junjie Chen,et al.  RPA-Binding Protein ETAA1 Is an ATR Activator Involved in DNA Replication Stress Response , 2016, Current Biology.

[47]  M. Mann,et al.  Activation of the ATR kinase by the RPA-binding protein ETAA1 , 2016, Nature Cell Biology.

[48]  A. Lau,et al.  Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase. , 2016, Journal of medicinal chemistry.

[49]  M. Gatei,et al.  ATM-Dependent Phosphorylation of All Three Members of the MRN Complex: From Sensor to Adaptor , 2015, Biomolecules.

[50]  L. Panasci,et al.  Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan , 2015, Front. Pharmacol..

[51]  A. Ryan,et al.  ATM and ATR as therapeutic targets in cancer. , 2015, Pharmacology & therapeutics.

[52]  R. Melero,et al.  Structure and Assembly of the PI3K-like Protein Kinases (PIKKs) Revealed by Electron Microscopy , 2015 .

[53]  H. Lieberman,et al.  DNA Damage Response Genes and the Development of Cancer Metastasis , 2014, Radiation research.

[54]  Linda Z. Shi,et al.  The Interaction of CtIP and Nbs1 Connects CDK and ATM to Regulate HR–Mediated Double-Strand Break Repair , 2013, PLoS genetics.

[55]  S. Elledge,et al.  Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. , 2013, Cancer research.

[56]  F. D. D. Fagagna,et al.  Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer , 2012, Nature Reviews Cancer.

[57]  R. Griffin,et al.  Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family. , 2012, Bioorganic & medicinal chemistry letters.

[58]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[59]  P. Reaper,et al.  Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. , 2011, Nature chemical biology.

[60]  Fiona A. Stewart,et al.  Strategies to improve radiotherapy with targeted drugs , 2011, Nature Reviews Cancer.

[61]  A. Nakagawara,et al.  Role of p53 in Cell Death and Human Cancers , 2011, Cancers.

[62]  S. Jackson,et al.  Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. , 2011, Genes & development.

[63]  A. Sancar,et al.  Reconstitution of RPA-covered single-stranded DNA-activated ATR-Chk1 signaling , 2010, Proceedings of the National Academy of Sciences.

[64]  J. Hoeijmakers.  DNA damage, aging, and cancer. , 2009, The New England journal of medicine.

[65]  D. Cortez,et al.  Common mechanisms of PIKK regulation. , 2009, DNA repair.

[66]  L. Zou,et al.  Single-stranded DNA orchestrates an ATM-to-ATR switch at DNA breaks. , 2009, Molecular cell.

[67]  R. Zhao,et al.  TopBP1 activates ATR through ATRIP and a PIKK regulatory domain. , 2008, Genes & development.

[68]  Anindya Dutta,et al.  ATR Pathway Is the Primary Pathway for Activating G2/M Checkpoint Induction After Re-replication* , 2007, Journal of Biological Chemistry.

[69]  Z. Herceg,et al.  Orchestration of chromatin-based processes: mind the TRRAP , 2007, Oncogene.

[70]  B. A. Ballif,et al.  ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage , 2007, Science.

[71]  B. Scott.  Low-Dose Radiation-Induced Protective Process and Implications for Risk Assessment, Cancer Prevention, and Cancer Therapy , 2007, Dose-response : a publication of International Hormesis Society.

[72]  Michael B Yaffe,et al.  p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. , 2007, Cancer cell.

[73]  Xiaofeng Jiang,et al.  The FATC Domains of PIKK Proteins Are Functionally Equivalent and Participate in the Tip60-dependent Activation of DNA-PKcs and ATM* , 2006, Journal of Biological Chemistry.

[74]  Xiaofeng Jiang,et al.  A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[75]  E. Conti,et al.  Nonsense-mediated mRNA decay: molecular insights and mechanistic variations across species. , 2005, Current opinion in cell biology.

[76]  Ji-Hoon Lee,et al.  ATM Activation by DNA Double-Strand Breaks Through the Mre11-Rad50-Nbs1 Complex , 2005, Science.

[77]  Daigo Inoue,et al.  Chk1, but not Chk2, inhibits Cdc25 phosphatases by a novel common mechanism , 2004, The EMBO journal.

[78]  David J. Chen,et al.  Role of DNA-PK in the cellular response to DNA double-strand breaks. , 2004, DNA repair.

[79]  P. Jeggo,et al.  An overview of three new disorders associated with genetic instability: LIG4 syndrome, RS-SCID and ATR-Seckel syndrome. , 2004, DNA repair.

[80]  Sonnet J. H. Arlander,et al.  Dial 9-1-1 for DNA damage: the Rad9-Hus1-Rad1 (9-1-1) clamp complex. , 2004, DNA repair.

[81]  N. Larebeke,et al.  Endogenous DNA damage in humans: a review of quantitative data , 2004 .

[82]  A. Anderson.  The process of structure-based drug design. , 2003, Chemistry & biology.

[83]  M. Donzelli,et al.  Regulating mammalian checkpoints through Cdc25 inactivation , 2003, EMBO reports.

[84]  Stephen J. Elledge,et al.  Sensing DNA Damage Through ATRIP Recognition of RPA-ssDNA Complexes , 2003, Science.

[85]  P. Jeggo,et al.  Clinical Impact of ATR Checkpoint Signalling Failure in Humans , 2003, Cell cycle.

[86]  Judith A. Goodship,et al.  A splicing mutation affecting expression of ataxia–telangiectasia and Rad3–related protein (ATR) results in Seckel syndrome , 2003, Nature Genetics.

[87]  M. Kastan,et al.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.

[88]  Jun Qin,et al.  ATR and ATRIP: Partners in Checkpoint Signaling , 2001, Science.

[89]  H. Piwnica-Worms,et al.  ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1 , 2001, Molecular and Cellular Biology.

[90]  N. Mailand,et al.  The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesis , 2001, Nature.

[91]  Y. Shiloh,et al.  Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response , 2000, Nature.

[92]  E. Sonnhammer,et al.  FAT: a novel domain in PIK-related kinases. , 2000, Trends in biochemical sciences.

[93]  D. Baltimore,et al.  ATR disruption leads to chromosomal fragmentation and early embryonic lethality. , 2000, Genes & development.

[94]  J. Sarkaria,et al.  Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. , 1999, Cancer research.

[95]  S. Seal,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[96]  M. Meyn.  Ataxia‐telangiectasia, cancer and the pathobiology of the ATM gene , 1999, Clinical genetics.

[97]  Y. Yamaguchi-Iwai,et al.  Homologous recombination and non‐homologous end‐joining pathways of DNA double‐strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells , 1998, The EMBO journal.

[98]  L. Hartwell,et al.  Integrating genetic approaches into the discovery of anticancer drugs. , 1997, Science.

[99]  S. Wallace.  DNA damages processed by base excision repair: biological consequences. , 1994, International journal of radiation biology.

[100]  T. Lindahl.  Instability and decay of the primary structure of DNA , 1993, Nature.

[101]  S. Friend,et al.  Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[102]  E. Kohn,et al.  PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[103]  H. Pospiech,et al.  Function of TopBP1 in genome stability. , 2010, Sub-cellular biochemistry.

[104]  J. Nickoloff,et al.  Regulation of DNA double-strand break repair pathway choice , 2008, Cell Research.

[105]  R. Gatti,et al.  Diversity of ATM gene mutations detected in patients with ataxia‐telangiectasia , 1997, Human mutation.